TY - JOUR
T1 - Population Pharmacokinetics and Exposure–Response of Lithium Carbonate in Patients Based on Tubular Reabsorption Mechanisms
AU - Yamaguchi, Daichi
AU - Tsuji, Yasuhiro
AU - Sonoda, Miki
AU - Shin, Kenji
AU - Kito, Hiroko
AU - Ogami, Chika
AU - Kasai, Hidefumi
AU - To, Hideto
AU - Kamimura, Hidetoshi
N1 - Funding Information:
Funding This study was supported by a grant from SENSHIN Medical Research Foundation and Takeda Science Foundation.
PY - 2019/6/1
Y1 - 2019/6/1
N2 - Background and Objective: Lithium, which is used to treat bipolar disorder, has a narrow therapeutic blood concentration range and quickly reaches clinically toxic levels. We performed a population pharmacokinetic analysis with a lithium tubular reabsorption model including urinary pH and investigated the relationship between blood lithium concentration and tremor as a side effect. Methods: Routine clinical data, including 389 serum concentrations, were collected from 214 patients orally administered an adjusted amount of lithium carbonate. Pharmacokinetics were described using a one-compartment distribution model with first-order absorption and elimination. The fractions of the MID (Li+ + LiCO3−) and ION (2Li+ + CO32−) forms were calculated using the Henderson–Hasselbalch equation, and the influences of these fractions on clearance (CL) were evaluated. The rate of tremor development was analyzed using a logit model. Results: Oral apparent CL (CL/F) was explained by nonrenal CL and renal CL, and renal CL was varied by the fractions of lithium forms influenced by urinary pH. The contribution of MID to CL was slightly larger than that of ION. The rate of tremor development was estimated to be more than 30% when the trough lithium concentration was greater than 1.26 mEq L−1. Conclusion: Renal function and urinary pH are important indices in lithium treatment, so the serum concentration of lithium may be predicted based on the renal function and urinary pH.
AB - Background and Objective: Lithium, which is used to treat bipolar disorder, has a narrow therapeutic blood concentration range and quickly reaches clinically toxic levels. We performed a population pharmacokinetic analysis with a lithium tubular reabsorption model including urinary pH and investigated the relationship between blood lithium concentration and tremor as a side effect. Methods: Routine clinical data, including 389 serum concentrations, were collected from 214 patients orally administered an adjusted amount of lithium carbonate. Pharmacokinetics were described using a one-compartment distribution model with first-order absorption and elimination. The fractions of the MID (Li+ + LiCO3−) and ION (2Li+ + CO32−) forms were calculated using the Henderson–Hasselbalch equation, and the influences of these fractions on clearance (CL) were evaluated. The rate of tremor development was analyzed using a logit model. Results: Oral apparent CL (CL/F) was explained by nonrenal CL and renal CL, and renal CL was varied by the fractions of lithium forms influenced by urinary pH. The contribution of MID to CL was slightly larger than that of ION. The rate of tremor development was estimated to be more than 30% when the trough lithium concentration was greater than 1.26 mEq L−1. Conclusion: Renal function and urinary pH are important indices in lithium treatment, so the serum concentration of lithium may be predicted based on the renal function and urinary pH.
UR - http://www.scopus.com/inward/record.url?scp=85058074228&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85058074228&partnerID=8YFLogxK
U2 - 10.1007/s13318-018-0536-0
DO - 10.1007/s13318-018-0536-0
M3 - Article
C2 - 30536114
AN - SCOPUS:85058074228
SN - 0378-7966
VL - 44
SP - 329
EP - 338
JO - European Journal of Drug Metabolism and Pharmacokinetics
JF - European Journal of Drug Metabolism and Pharmacokinetics
IS - 3
ER -